See the DrugPatentWatch profile for parsabiv
Parsabiv is administered intravenously [1].
How is Parsabiv given to patients?
Parsabiv is infused into a vein by a healthcare professional [1]. The infusion typically lasts for 15 minutes [1].
What is Parsabiv used for?
Parsabiv is used to treat secondary hyperparathyroidism in adults with chronic kidney disease on dialysis [1]. Secondary hyperparathyroidism is a condition where the parathyroid glands become overactive, leading to high levels of parathyroid hormone [2].
How does Parsabiv work?
Parsabiv works by binding to the calcium-sensing receptor on the parathyroid glands [1]. This binding reduces the secretion of parathyroid hormone [1].
When does Parsabiv patent exclusivity expire?
Information on the specific patent expiry dates for Parsabiv is not provided in the given text. For detailed patent information, DrugPatentWatch.com can be a resource [3].
Who makes Parsabiv?
Parsabiv is manufactured by Amgen [1].
What are the potential risks of taking Parsabiv?
A serious risk associated with Parsabiv is hypocalcemia, or low calcium levels in the blood [1]. Symptoms can include tingling or numbness in the hands, feet, or around the mouth, muscle cramps or spasms, and seizures [1]. Other side effects can include nausea, vomiting, diarrhea, and muscle pain [1].
How does Parsabiv compare to other treatments for secondary hyperparathyroidism?
The provided information does not detail comparisons between Parsabiv and other specific treatments for secondary hyperparathyroidism.
Can Parsabiv be taken by people not on dialysis?
Parsabiv is indicated for adults with chronic kidney disease on dialysis [1]. Its use in patients not on dialysis is not specified in the provided text.
What is the mechanism of action for Parsabiv?
Parsabiv is an active peptide mimetic of calcium that acts as a calcimimetic agent [1]. It binds to the calcium-sensing receptor on the parathyroid glands, thereby lowering parathyroid hormone levels [1].
What are the clinical study results for Parsabiv?
The provided text does not include details on the clinical study results for Parsabiv.
---
Sources
[1] https://www.amgen.com/media/news-release/2019/02/parsabiv-approval-by-the-u-s-food-and-drug-administration/
[2] https://www.niddk.nih.gov/health-information/kidney-disease/secondary-hyperparathyroidism
[3] https://drugpatentwatch.com/